CLAIMS

1. Use of an effective amount of an antibody and methotrexate in the manufacture of a medicament for a concurrent or sequential therapy for treating rheumatoid arthritis in a subject, wherein the antibody comprises a heavy chain variable region (VH) comprising the sequence of SEQ ID NO:2 and a light chain variable region (VL) comprising the sequence of SEQ ID NO:3, wherein the subject was previously ineffectively treated for rheumatoid arthritis by administration of methotrexate.

2. The use of claim 1, wherein the antibody is to be administered at a dose of between 50 and 150 mg every week.

3. The use of claim 1, wherein the antibody is to be administered at a dose of between 100 and 200 mg every two weeks.

4. The use of any of claims 1 and 3, wherein the antibody is to be administered at a dose of 150 mg every two weeks or 200 mg every two weeks.

5. The use of claim 4, wherein the subject achieves at least a 20% improvement in the American College of Rheumatology (ACR) core set disease index after treatment after 12 weeks of treatment or after 24 weeks of treatment.

6. The use of claim 4, wherein the subject achieves at least a 50% improvement in the American College of Rheumatology (ACR) core set disease index after treatment after 12 weeks of treatment.

7. The use of claim 4, wherein the subject achieves at least a 70% improvement in the American College of Rheumatology (ACR) core set disease index after treatment after 12 weeks of treatment.

8. The use of any of claims 1 to 7, wherein the methotrexate is to be administered at a dose of between 6 to 25 mg per week.

9. The use of any of claims 1 to 8, wherein the antibody is sarilumab.

10. The use of any of claims 1 to 9, wherein the antibody is to be administered subcutaneously to the subject.